Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.38 |
| ▸ | GAK | O14976 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336346 | 0.91 | MAPT (0.46) | MAPTRAB9ALRRK2GAK | |
| SCHEMBL24865442 | 0.91 | MAPT (0.46) | MAPTRAB9ALRRK2GAK | |
| SCHEMBL30336264 | 0.82 | ALDH1A1 (0.43) | MAPTGRM4RAB9ANSD2NOTUM | |
| SCHEMBL24865384 | 0.82 | ALDH1A1 (0.43) | MAPTGRM4RAB9ANSD2NOTUM | |
| SCHEMBL30336715 | 0.76 | MAPT (0.46) | MAPTRAB9ALRRK2GAKSYK | |
| SCHEMBL30336395 | 0.76 | MAPT (0.46) | MAPTGRM4LRRK2SYK | |
| SCHEMBL24864844 | 0.76 | MAPT (0.46) | MAPTRAB9ALRRK2GAKSYK | |
| SCHEMBL24865662 | 0.76 | MAPT (0.46) | MAPTGRM4LRRK2SYK | |
| SCHEMBL24865522 | 0.76 | MAPT (0.46) | MAPTRAB9ALRRK2GAKSYK | |
| SCHEMBL24865648 | 0.76 | GRM4 (0.40) | MAPTGRM4NSD2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | MAPT 3110/4885GRM4 581/4885RAB9A 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.